ET190L1-ARTEMIS T cells (Eureka Therapeutics)

N/A

Report date: 2025/12/31 20:01:55

Base Information

Drug NameET190L1-ARTEMIS T cells (Eureka Therapeutics)

Drug Alias NameET190L1ET190L1-ARTEMIET-190ET190

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionB-lymphocyte antigen CD19 inhibitorsT lymphocyte replacements

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-CellLeukemia, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesMainland China

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaPending

Originator CompaniesEureka Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesEureka Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsLymphoma, B-CellLeukemia, B-Cell

Other Information

ATC CodeN/A